ENOV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Enovis Corp (ENOV) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows some positive catalysts such as improving financial health and organic growth, the recent price decline, lack of strong trading signals, and weak financial performance in terms of net income and EPS make it prudent to hold off on investing until further positive developments occur.
The technical indicators are neutral overall. The MACD is positive but contracting, the RSI is neutral at 50.341, and moving averages are converging. The stock is trading near a key support level (S1: 22.437), with resistance at R1: 25.906. No strong bullish or bearish signals are present.
Analysts have a generally positive outlook, with multiple Buy ratings and price targets ranging from $40 to $50, indicating potential upside.
The company reported 6% organic revenue growth in Q4 2025 and expects 4%-6% organic growth in
Positive free cash flow of $20 million in 2025 reflects improving financial health.
The stock price has declined significantly, with a 5.70% drop in the regular market and additional declines in pre- and post-market trading.
Net income and EPS have dropped significantly YoY, with net income down 25.98% and EPS down 27.66%.
The market perceives the company as under-scaled and exposed to unattractive mature markets and higher tariffs.
In Q4 2025, revenue increased by 2.64% YoY to $576 million, and gross margin improved by 6.33% to 53.93%. However, net income dropped by 25.98% YoY to -$520.59 million, and EPS fell by 27.66% to -9.1. The company achieved positive free cash flow of $20 million for 2025, signaling some improvement in financial health.
Analysts are generally positive on Enovis, with multiple Buy ratings and price targets ranging from $40 to $50. Analysts highlight the company's improving financial profile, recovering end markets, and strong positioning in the MedTech sector. However, some concerns remain about sector rotation, ACA/Medicare changes, and tariff exposure.
